Eli Lilly Says Weight Loss Pill On Track for 2Q Launch in US

Summary

Eli Lilly CFO Lucas Montarce spoke with Katie Greifeld about the company's 2026 guidance, Q4 results, and key product catalysts. He said Lilly expects 25% revenue growth at the midpoint, driven by broad portfolio momentum and volume growth that should offset low-to-mid-teens price erosion. Montarce also highlighted the upcoming Q2 regulatory decision for Lilly's oral weight-loss pill, Medicare access expansion, and the recent quick-pen approval.

• Lilly guides to 25% revenue growth at the midpoint for 2026 after 43% Q4 revenue growth.
• Management expects volume growth to more than offset low-to-mid-teens price erosion.
• US anti-obesity market grew 85% in Q4, and Lilly outpaced that growth.
• Lilly's oral weight-loss pill is on track for FDA action as early as Q2 2026.
• Medicare access for anti-obesity medications is expected by July, covering over 40 million patients with a $50 copay.
• Lilly plans to launch its recently approved quick-pen device within 30 days through Medicare and direct-to-patient channels.